Nervous Disorder TRIZ Cases

A sodium oxybate tablet uses a water-resistant film coating to enable rapid dissolution within one hour.

A quinolinyl compound inhibits tyrosine kinase and histone deacetylase simultaneously.

Calcitonin and CGRP levels predict IL-33 antagonist response, resolving ineffective patient selection.

A universal escapement with integral glass and multi-angle imaging devices reads product indicia during linear transport.

Segmented therapy targets EGFR gene fusions in glioblastoma using purified fusion proteins to inhibit kinase activity and slow tumor growth.

A delivery device uses an interpenetrating polymer network substrate to form continuous pathways for chemical substance transport.

Crystallization inhibitors stabilize amorphous compounds of Formula I against recrystallization, preserving bioavailability for schizophrenia treatment.

Recombinant human ApoE2 protein modulates the lipidome to overcome limited efficacy of current Alzheimer's treatments.

Uric acid mitigates oxidative stress and mitochondrial dysfunction to reduce brain damage and improve survival rates after mechanical thrombectomy.

Deuterated 2-oxo-1,2-dihydro-quinoline compounds slow oxidative metabolism by cytochrome P450 enzymes through the kinetic isotope effect to extend half-life.

Specific small molecule compounds bind to pre-mRNA and splicing machinery components to modulate nucleic acid splicing events.

Targeted AAV delivery of CNTFRa, CLC, and CLF genes to skeletal muscle avoids systemic side effects while enhancing endogenous neuroprotective mechanisms.

Modified AAV2.5 capsids introduce dual glycan binding sites to enhance transduction efficiency in neural tissues.

A TfR-binding domain fuses to acid sphingomyelinase to transport the enzyme across the blood-brain barrier.

Targeting Factor 11 via antisense modulation improves anticoagulant predictability while avoiding bleeding complications from broad-spectrum agents.

Incorporating specific peptide sequences into AAV capsids directs vectors to central nervous system cells, resolving systemic administration trade-offs.

Narrow HCG dosage ranges reset pain transmission pathways to address central sensitization without opioid toxicity.

An anti-alpha-synuclein antibody specifically binds to protein aggregates and promotes phagocytic uptake by nerve cells.

Developed monoclonal antibodies target pathological tau conformations to inhibit aggregation and reduce neurodegeneration spread.

Injecting hyaluronic acid reduces pressure on compressed nerves, improving wound healing and lowering recurrence rates after neurolysis.

Peptidomimetic macrocycles bind MDM2 and MDMX to restore p53 activity, addressing ineffective treatments for solid tumors with p53 mutations.

Deuterium substitution alters metabolic kinetics to improve depressive symptoms while avoiding akathisia and suicidal ideation.

Formula I thyromimetic compounds selectively activate TRβ receptors to treat neurodegenerative and fibrotic diseases without cardiotoxicity.

Combining edaravone with borneol overcomes limited monotherapy efficacy by extending survival time and improving motor function in transgenic models.

Pregnant women receive bovine intestinal alkaline phosphatase to reduce gastrointestinal dysbiosis and improve offspring neurodevelopmental outcomes.

Stoichiometric excess organic acids buffer weak organic base drugs to pH 3-6.5, resolving poor water solubility and salt instability.

Antibodies targeting the midkine N-domain resolve limited C-domain efficacy by inhibiting cell migration in inflammatory disorders.

Optimized CD3 binding domains improve bispecific antibody stability and reduce cytokine release syndrome risk during cancer treatment.

Engineered stem cells generate durable immunity by producing broadly neutralizing antibodies while evading host rejection.